DK1926483T3 - Behandling af autoimmune sygdomme - Google Patents

Behandling af autoimmune sygdomme

Info

Publication number
DK1926483T3
DK1926483T3 DK06793341.6T DK06793341T DK1926483T3 DK 1926483 T3 DK1926483 T3 DK 1926483T3 DK 06793341 T DK06793341 T DK 06793341T DK 1926483 T3 DK1926483 T3 DK 1926483T3
Authority
DK
Denmark
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
invention describes
Prior art date
Application number
DK06793341.6T
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1926483T3 publication Critical patent/DK1926483T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK06793341.6T 2005-09-09 2006-09-07 Behandling af autoimmune sygdomme DK1926483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
DK1926483T3 true DK1926483T3 (da) 2011-03-14

Family

ID=37056992

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10174280.7T DK2295049T3 (da) 2005-09-09 2006-09-07 Behandling af autoimmunsygdomme
DK06793341.6T DK1926483T3 (da) 2005-09-09 2006-09-07 Behandling af autoimmune sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10174280.7T DK2295049T3 (da) 2005-09-09 2006-09-07 Behandling af autoimmunsygdomme

Country Status (29)

Country Link
US (1) US20080200438A1 (da)
EP (2) EP2295049B1 (da)
JP (4) JP5244598B2 (da)
KR (3) KR101476591B1 (da)
CN (1) CN101257899B (da)
AT (1) ATE489948T1 (da)
AU (2) AU2006289100B2 (da)
BR (1) BRPI0615906A2 (da)
CA (2) CA2820510A1 (da)
CY (1) CY1111285T1 (da)
DE (1) DE602006018629D1 (da)
DK (2) DK2295049T3 (da)
ES (2) ES2357426T3 (da)
HK (1) HK1149906A1 (da)
IL (2) IL189665A (da)
JO (1) JO2655B1 (da)
MA (1) MA29787B1 (da)
MX (1) MX2008003170A (da)
NO (1) NO20081727L (da)
NZ (2) NZ588372A (da)
PL (2) PL2295049T3 (da)
PT (2) PT2295049E (da)
RU (2) RU2493840C2 (da)
SG (1) SG165364A1 (da)
SI (2) SI1926483T1 (da)
TN (1) TNSN08103A1 (da)
TW (2) TWI376223B (da)
WO (1) WO2007028821A2 (da)
ZA (1) ZA200801694B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
BRPI0516337A (pt) 2004-10-12 2008-04-29 Kyorin Seiyaku Kk processo para a produção de 2- amino-2-[4-(3-benziloxifeniltio) -2- (clorofenil} etil] - 1,3 - hidrocloreto de propanediol e hidratos dos mesmos e produtos intermerdiários para a produção dos mesmos
CA2624909C (en) * 2005-10-07 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RS53080B (en) * 2006-08-08 2014-06-30 Kyorin Pharmaceutical Co. Ltd. AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT
MY146775A (en) * 2006-08-08 2012-09-28 Kyorin Seiyaku Kk Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
TW201000109A (en) * 2008-05-20 2010-01-01 Kyorin Seiyaku Kk Agent for induction/maintenance of remission
EA019808B1 (ru) * 2008-08-18 2014-06-30 Новартис Аг Производные аминоспиртов, предназначенные для лечения демиелинизирующих периферических невропатий
MA34285B1 (fr) * 2010-05-06 2013-06-01 Novartis Ag Traitement de maladies autoimmunes
MX2012012925A (es) * 2010-05-06 2012-12-17 Novartis Ag Regimen de dosificacion de derivados de sulfuro de diarilo.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
CN1329372C (zh) * 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA05003080A (es) 2002-09-19 2005-06-15 Kyorin Seiyaku Kk Derivado de amino alcohol, sales de los mismos y agentes inmunosupresores.
PL408347A1 (pl) * 2002-09-24 2014-08-18 Novartis Ag Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
RU2005108608A (ru) * 2002-09-28 2005-10-27 МакНЕЙЛ-ППС, ИНК. (US) Дозированная форма немедленного высвобождения, содержащая оболочку с отверстиями
KR101005171B1 (ko) * 2003-02-18 2011-01-04 교린 세이야꾸 가부시키 가이샤 아미노포스폰산 유도체와 그 부가염 및 s1p 수용체조절제
HUE028247T2 (en) * 2003-04-08 2016-12-28 Novartis Ag A solid oral composition comprising S1P receptor agonist and sugar alcohol
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
CA2535704C (en) * 2003-08-28 2012-12-11 Novartis Ag Aminopropanol derivatives
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
SG158096A1 (en) * 2004-11-29 2010-01-29 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20140117704A (ko) 2014-10-07
SI1926483T1 (sl) 2011-04-29
JP2013010802A (ja) 2013-01-17
JP2009507810A (ja) 2009-02-26
HK1149906A1 (en) 2011-10-21
RU2008113187A (ru) 2009-10-20
RU2493840C2 (ru) 2013-09-27
ATE489948T1 (de) 2010-12-15
KR20140019033A (ko) 2014-02-13
CA2620554A1 (en) 2007-03-15
EP2295049B1 (en) 2014-11-26
ES2357426T3 (es) 2011-04-26
CA2820510A1 (en) 2007-03-15
CY1111285T1 (el) 2015-08-05
MX2008003170A (es) 2008-03-18
CA2620554C (en) 2013-12-17
JO2655B1 (en) 2012-06-17
JP2017019854A (ja) 2017-01-26
CN101257899B (zh) 2012-10-03
PL1926483T3 (pl) 2011-05-31
NZ566137A (en) 2011-05-27
AU2010224355B2 (en) 2012-03-29
ZA200801694B (en) 2009-09-30
JP5244598B2 (ja) 2013-07-24
MA29787B1 (fr) 2008-09-01
CN101257899A (zh) 2008-09-03
PT2295049E (pt) 2015-03-02
WO2007028821A2 (en) 2007-03-15
KR101476451B1 (ko) 2014-12-24
KR20080046231A (ko) 2008-05-26
JP6077265B2 (ja) 2017-02-08
SI2295049T1 (sl) 2015-03-31
IL233328A0 (en) 2014-08-31
PL2295049T3 (pl) 2015-04-30
AU2010224355A1 (en) 2010-10-14
EP1926483A2 (en) 2008-06-04
DE602006018629D1 (de) 2011-01-13
KR101476591B1 (ko) 2014-12-24
PT1926483E (pt) 2011-03-03
TW200803829A (en) 2008-01-16
TW201034659A (en) 2010-10-01
NZ588372A (en) 2012-03-30
US20080200438A1 (en) 2008-08-21
TNSN08103A1 (en) 2009-07-14
ES2529724T3 (es) 2015-02-25
IL189665A (en) 2014-07-31
JP2015025002A (ja) 2015-02-05
RU2424795C2 (ru) 2011-07-27
TWI376223B (en) 2012-11-11
AU2006289100B2 (en) 2010-07-22
DK2295049T3 (da) 2015-02-23
EP1926483B1 (en) 2010-12-01
NO20081727L (no) 2008-06-06
WO2007028821A3 (en) 2007-05-03
RU2011111117A (ru) 2012-09-27
BRPI0615906A2 (pt) 2011-05-31
AU2006289100A1 (en) 2007-03-15
EP2295049A1 (en) 2011-03-16
TWI372620B (en) 2012-09-21
IL189665A0 (en) 2008-06-05
SG165364A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
DK1926483T3 (da) Behandling af autoimmune sygdomme
TW200509892A (en) Novel aminobenzophenone compounds
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
EA201070247A1 (ru) Ингибиторы протеасом
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20072092L (no) Sulfonamidforbindelser
EA200802054A1 (ru) Ингибиторы фермента
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
EA201300871A1 (ru) ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
EA200701815A1 (ru) 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
WO2009051661A3 (en) Substituted aryl alkylamino-oxy-analogs and uses thereof